Genomic testing links 'exceptional' drug response to rare mutations in bladder cancer

A patient with advanced bladder cancer in a phase I trial had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, and genomic profiling of his tumor revealed two alterations that may have led to this exceptional response. This information can help identify cancer patients who may respond to everolimus, according to the report published in Cancer Discovery. Read more here.